The role of paraoxonase 1 in the detoxification of homocysteine thiolactone

Advances in Experimental Medicine and Biology

Volumn 660, Issue , 2010, Pages 113-127

  Jakubowski, Hieronim ^a  

^a NONE

Author keywords

Atherosclerosis; Autoantibodies; CBS; Fibrinogen; Homocysteine thiolactone; Hyperhomocysteinemia; Immune activation; MTHFR; Paraoxonase thiolactonase; Protein N homocysteinylation; Thrombosis

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; FIBRINOGEN; HOMOCYSTEINE THIOLACTONE;

AMINO ACID METABOLISM; ARTICLE; AUTOIMMUNITY; BIOACCUMULATION; DETOXIFICATION; HUMAN; HYPERHOMOCYSTEINEMIA; IMMUNOGENICITY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN MODIFICATION; THROMBOGENESIS;

ANIMALS; ARYLDIALKYLPHOSPHATASE; AUTOIMMUNITY; FIBRINOGEN; HOMOCYSTEINE; HUMANS; IMMUNE SYSTEM; METHIONINE-TRNA LIGASE; MICE; MICE, TRANSGENIC; MODELS, BIOLOGICAL; RISK FACTORS; THROMBOSIS;

MAMMALIA;

EID: 79951688566     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-60761-350-3_11     Document Type: Article

References (77)

1. Beltowski J, Wojcicka G, Jamroz A. Leptin decreases plasma paraoxonase 1 (PON1) activity and induces oxidative stress: the possible novel mechanism for proatherogenic effect of chronic hyperleptinemia. Atherosclerosis. 2003 Sep;170(1):21-29. (Pubitemid 37086705)
2. Beltowski J, Wojcicka G, Jamroz-Wisniewska A, Marciniak A. Liver X receptor agonist, T0901317, normalizes plasma PON1 activity and reduces protein homocysteinylation in rats with experimental hyperleptinemia. 3rd International Conference on Paraoxonases; 2008; Los Angeles, CA. 2008.
3. Bogdanski P, Pupek-Musialik D, Dytfeld J, Lacinski M, Jablecka A, Jakubowski H. Plasma homocysteine is a determinant of tissue necrosis factor-alpha in hypertensive patients. Biomed Pharmacother. 2007 Dec 3;62:360-365
4. Bonaa KH, Njolstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006 Apr 13;354(15):1578-1588.
5. Chwatko G, Boers GH, Strauss KA, Shih DM, Jakubowski H. Mutations in methylenetetrahydrofolate reductase or cystathionine beta-synthase gene, or a high-methionine diet, increase homocysteine thiolactone levels in humans and mice. Faseb J. 2007 Jun;21(8):1707-1713. (Pubitemid 46855616)
6. Chwatko G, Jakubowski H. The determination of homocysteine-thiolactone in human plasma. Anal Biochem. 2005 Feb 15;337(2):271-277. (Pubitemid 40187254)
7. Chwatko G, Jakubowski H. Urinary excretion of homocysteine-thiolactone in humans. Clin Chem. 2005 Feb;51(2):408-415. (Pubitemid 40175812)
8. Clarke R, Lewington S, Sherliker P, Armitage J. Effects of B-vitamins on plasma homocysteine concentrations and on risk of cardiovascular disease and dementia. Curr Opin Clin Nutr Metab Care. 2007 Jan;10(1):32-39. (Pubitemid 44901131)
9. Domagała TB, Łacinski M, Trzeciak WH,Mackness B, Mackness MI, Jakubowski H. The correlation of homocysteine-thiolactonase activity of the paraoxonase (PON1) protein with coronary heart disease status. Cell Mol Biol (Noisy-le-grand). 2006;52(5):4-10. (Pubitemid 46683309)
10. Donahue S, Struman JA, Gaull G. Arteriosclerosis due to homocyst(e)inemia. Failure to reproduce the model in weanling rabbits. Am J Pathol. 1974 Nov;77(2):167-163.
11. Durga J, van Boxtel MP, Schouten EG, Kok FJ, Jolles J, Katan MB, et al. Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomised, double blind, controlled trial. Lancet. 2007 Jan 20;369(9557):208-216. (Pubitemid 46107683)
12. Endo N, Nishiyama K, Otsuka A, Kanouchi H, Taga M, Oka T. Antioxidant activity of vitamin B6 delays homocysteine-induced atherosclerosis in rats. Br J Nutr. 2006 Jun;95(6): 1088-1093. (Pubitemid 43985987)
13. Ferretti G, Bacchetti T, Marotti E, Curatola G. Effect of homocysteinylation on human highdensity lipoproteins: a correlation with paraoxonase activity. Metabolism. 2003 Feb;52(2): 146-151. (Pubitemid 36388834)
14. Ferretti G, Bacchetti T, Moroni C, Vignini A, Nanetti L, Curatola G. Effect of homocysteinylation of low density lipoproteins on lipid peroxidation of human endothelial cells. J Cell Biochem. 2004 May 15;92(2):351-360.
15. Glowacki R, Jakubowski H. Cross-talk between Cys34 and lysine residues in human serum albumin revealed by N-homocysteinylation. J Biol Chem. 2004 Mar 19;279(12):10864-10871. (Pubitemid 38401576)
16. GuW, Lu J, Yang G, Dou J, Mu Y, Meng J, et al. Plasma homocysteine thiolactone associated with risk of macrovasculopathy in Chinese patients with type 2 diabetes mellitus. Adv Ther. 2008 Sep;25(9):914-924.
17. Harker LA, Slichter SJ, Scott CR, Ross R. Homocystinemia. Vascular injury and arterial thrombosis. N Engl J Med. 1974 Sep 12;291(11):537-543.
18. Hossain GS, van Thienen JV, Werstuck GH, Zhou J, Sood SK, Dickhout JG, et al. TDAG51 is induced by homocysteine, promotes detachment-mediated programmed cell death, and contributes to the development of atherosclerosis in hyperhomocysteinemia. J Biol Chem. 2003 Aug 8;278(32):30317-30327. (Pubitemid 36962426)
19. Huang RF, Huang SM, Lin BS,Wei JS, Liu TZ. Homocysteine thiolactone induces apoptotic DNA damage mediated by increased intracellular hydrogen peroxide and caspase 3 activation in HL-60 cells. Life Sci. 2001 May 11;68(25):2799-2811.
20. Jakubowski H. Proofreading in vivo: editing of homocysteine by methionyl-tRNA synthetase in the yeast Saccharomyces cerevisiae. Embo J. 1991 Mar;10(3):593-598. (Pubitemid 21905512)
21. Jakubowski H. Metabolism of homocysteine thiolactone in human cell cultures. Possible mechanism for pathological consequences of elevated homocysteine levels. J Biol Chem. 1997 Jan 17;272(3):1935-1942. (Pubitemid 27043288)
22. Jakubowski H. Protein homocysteinylation: possible mechanism underlying pathological consequences of elevated homocysteine levels. Faseb J. 1999 Dec;13(15):2277-2283.
23. Jakubowski H. Homocysteine thiolactone: metabolic origin and protein homocysteinylation in humans. J Nutr. 2000 Feb;130(2S Suppl):377S-381S. (Pubitemid 30073754)
24. Jakubowski H. Calcium-dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation. J Biol Chem. 2000 Feb 11;275(6): 3957-3962. (Pubitemid 30094622)
25. Jakubowski H. Biosynthesis and reactions of homocysteine thiolactone. In: Jacobson D, Carmel R (eds. ). Homocysteine in Health and Disease. Cambridge, UK: Cambridge University Press; 2001. 21-31.
26. Jakubowski H. Translational accuracy of aminoacyl-tRNA synthetases: implications for atherosclerosis. J Nutr. 2001 Nov;131(11):2983S-2987S.
27. Jakubowski H. Protein N-homocysteinylation: implications for atherosclerosis. Biomed Pharmacother. 2001 Oct;55(8):443-447. (Pubitemid 32913568)
28. Jakubowski H. The determination of homocysteine-thiolactone in biological samples. Anal Biochem. 2002 Sep 1;308(1):112-119. (Pubitemid 35191644)
29. Jakubowski H. Homocysteine is a protein amino acid in humans. Implications for homocysteinelinked disease. J Biol Chem. 2002 Aug 23;277(34):30425-30428. (Pubitemid 34970732)
30. Jakubowski H. Molecular basis of homocysteine toxicity in humans. Cell Mol Life Sci. 2004 Feb;61(4):470-487. (Pubitemid 38316582)
31. Jakubowski H. Accuracy of aminoacyl-tRNA synthetases: Proofreading of amino acids. In: Ibba M, Francklyn C, Cusack S (eds. ). The Aminoacyl-tRNA Synthetases. Georgetown, TX: Landes Bioscience/Eurekah. com 2005. 384-396.
32. Jakubowski H. Anti-N-homocysteinylated protein autoantibodies and cardiovascular disease. Clin Chem Lab Med. 2005;43(10):1011-1014. (Pubitemid 41581953)
33. Jakubowski H. tRNA Synthetase Editing of Amino Acids. Encyclopedia of Life Sciences. Chichester, UK: John Wiley & Sons, Ltd; 2005. p. http://www.els.net/doi:10.1038/npg.els.0003933.
34. Jakubowski H. Pathophysiological consequences of homocysteine excess. J Nutr. 2006 Jun;136(6 Suppl):1741S-1749S. (Pubitemid 43765390)
35. Jakubowski H. The molecular basis of homocysteine thiolactone-mediated vascular disease. Clin Chem Lab Med. 2007;45(12):1704-1716. (Pubitemid 350232966)
36. Jakubowski H. New method for the determination of protein N-linked homocysteine. Anal Biochem. 2008 Sep 15;380(2):257-261.
37. Jakubowski H, Ambrosius WT, Pratt JH. Genetic determinants of homocysteine thiolactonase activity in humans: implications for atherosclerosis. FEBS Lett. 2001 Feb 23;491(1-2):35-39. (Pubitemid 32171996)
38. Jakubowski H, Boers GH, Strauss KA. Mutations in cystathionine beta-synthase or methylenetetrahydrofolate reductase gene increase N-homocysteinylated protein levels in humans. FASEB J. 2008;22:4071-4076.
39. Jakubowski H, Goldman E. Synthesis of homocysteine thiolactone by methionyl-tRNA synthetase in cultured mammalian cells. FEBS Lett. 1993 Feb 15;317(3):237-240. (Pubitemid 23045796)
40. Jakubowski H, Zhang L, Bardeguez A, Aviv A. Homocysteine thiolactone and protein homocysteinylation in human endothelial cells: implications for atherosclerosis. Circ Res. 2000 Jul 7;87(1):45-51. (Pubitemid 30456934)
41. Jarvik GP, Rozek LS, Brophy VH, Hatsukami TS, Richter RJ, Schellenberg GD, et al. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype. Arterioscler Thromb Vasc Biol. 2000 Nov;20(11):2441-2447.
42. Kamudhamas A, Pang L, Smith SD, Sadovsky Y, Nelson DM. Homocysteine thiolactone induces apoptosis in cultured human trophoblasts: a mechanism for homocysteine-mediated placental dysfunction? Am J Obstet Gynecol. 2004 Aug;191(2):563-571. (Pubitemid 39178715)
43. Kerkeni M, Tnani M, Chuniaud L, Miled A, Maaroufi K, Trivin F. Comparative study on in vitro effects of homocysteine thiolactone and homocysteine on HUVEC cells: evidence for a stronger proapoptotic and proinflammative homocysteine thiolactone. Mol Cell Biochem. 2006 Oct;291(1-2):119-126. (Pubitemid 44725310)
44. Kluijtmans LA, Boers GH, Kraus JP, van den Heuvel LP, Cruysberg JR, Trijbels FJ, et al. The molecular basis of cystathionine beta-synthase deficiency in Dutch patients with homocystinuria: effect of CBS genotype on biochemical and clinical phenotype and on response to treatment. Am J Hum Genet. 1999 Jul;65(1):59-67. (Pubitemid 30470449)
45. Lacinski M, SkorupskiW, Cieslinski A, Sokolowska J, Trzeciak WH, Jakubowski H. Determinants of homocysteine-thiolactonase activity of the paraoxonase-1 (PON1) protein in humans. Cell Mol Biol (Noisy-le-grand). 2004 Dec;50(8):885-893.
46. Lawrence de Koning AB, Werstuck GH, Zhou J, Austin RC. Hyperhomocysteinemia and its role in the development of atherosclerosis. Clin Biochem. 2003 Sep;36(6):431-441. (Pubitemid 37086702)
47. Lentz SR. Mechanisms of homocysteine-induced atherothrombosis. J Thromb Haemost. 2005 Aug;3(8):1646-1654. (Pubitemid 41716550)
48. Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr. 2006 Feb;83(2):456S-4560S.
49. Liu G, Nellaiappan K, Kagan HM. Irreversible inhibition of lysyl oxidase by homocysteine thiolactone and its selenium and oxygen analogues. Implications for homocystinuria. J Biol Chem. 1997 Dec 19;272(51):32370-32377. (Pubitemid 28011919)
50. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006 Apr 13;354(15):1567-1577.
51. Maestro de las Casas C, Epeldegui M, Tudela C, Varela-Moreiras G, Perez-Miguelsanz J. High exogenous homocysteine modifies eye development in early chick embryos. Birth Defects Res A Clin Mol Teratol. 2003 Jan;67(1):35-40. (Pubitemid 37238070)
52. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol. 1969 Jul;56(1):111-128.
53. Mercie P, Garnier O, Lascoste L, Renard M, Closse C, Durrieu F, et al. Homocysteine-thiolactone induces caspase-independent vascular endothelial cell death with apoptotic features. Apoptosis. 2000 Nov;5(5):403-411. (Pubitemid 32162622)
54. Mudd SH, Levy HL, Krauss JP. Disorders of transsulfuration. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW et al. (eds. ). The metabolic and molecular bases of inherited disease. 8th ed. New York: Mc Graw-Hill; 2001. 2007-2056.
55. Mudd SH, Skovby F, Levy HL, Pettigrew KD, Wilcken B, Pyeritz RE, et al. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet. 1985 Jan;37(1):1-31. (Pubitemid 15138674)
56. Najib S, Sanchez-Margalet V. Homocysteine thiolactone inhibits insulin-stimulated DNA and protein synthesis: possible role of mitogen-activated protein kinase (MAPK), glycogen synthase kinase-3 (GSK-3) and p70 S6K phosphorylation. J Mol Endocrinol. 2005 Feb;34(1):119-126. (Pubitemid 40305554)
57. Naruszewicz M, Olszewski AJ, Mirkiewicz E, McCully KS. Thiolation of low density lipoproteins by homocysteine thiolactone causes increased aggregation and altered interaction with cultured macrophages. Nutr Metab Cardiovasc Dis. 1994;4:70-77.
58. Perla-Kajan J, Marczak L, Kajan L, Skowronek P, Twardowski T, Jakubowski H. Modification by homocysteine thiolactone affects redox status of cytochrome c. Biochemistry. 2007 May 29;46(21):6225-6231. (Pubitemid 46842865)
59. Perla-Kajan J, Stanger O, Luczak M, Ziolkowska A, Malendowicz LK, Twardowski T, et al. Immunohistochemical detection of N-homocysteinylated proteins in humans and mice. Biomed Pharmacother. 2008 May 2;62(7):473-479.
60. Robert K, Chasse JF, Santiard-Baron D, Vayssettes C, Chabli A, Aupetit J, et al. Altered gene expression in liver from a murine model of hyperhomocysteinemia. J Biol Chem. 2003 Aug 22;278(34):31504-31511. (Pubitemid 37048327)
61. Rosenblatt D, Fenton W. Disorders of transsulfuration. In: Scriver C, Beaudet A, Sly W, Valle D, Childs B, Kinzler K, et al. (eds. ). The metabolic and molecular bases of inherited disease. 8th ed. New York: Mc Graw-Hill; 2001. 2007-2056.
62. Roybal CN, Yang S, Sun CW, Hurtado D, Vander Jagt DL, Townes TM, et al. Homocysteine increases the expression of vascular endothelial growth factor by a mechanism involving endoplasmic reticulum stress and transcription factor ATF4. J Biol Chem. 2004 Apr 9;279(15):14844-14852. (Pubitemid 38618874)
63. Sauls DL, Lockhart E, Warren ME, Lenkowski A, Wilhelm SE, Hoffman M. Modification of fibrinogen by homocysteine thiolactone increases resistance to fibrinolysis: a potential mechanism of the thrombotic tendency in hyperhomocysteinemia. Biochemistry. 2006 Feb 28;45(8):2480-2487.
64. Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 1998 Jul 16;394(6690):284-287. (Pubitemid 28335041)
65. Shishehbor MH, Oliveira LP, LauerMS, Sprecher DL,Wolski K, Cho L, et al. Emerging cardiovascular risk factors that account for a significant portion of attributable mortality risk in chronic kidney disease. Am J Cardiol. 2008 Jun 15;101(12):1741-1746.
66. Spence JD, Bang H, Chambless LE, Stampfer MJ. Vitamin Intervention For Stroke Prevention trial: an efficacy analysis. Stroke. 2005 Nov;36(11):2404- 2409. (Pubitemid 41566967)
67. Stefani M. Protein misfolding and aggregation: new examples in medicine and biology of the dark side of the protein world. Biochim Biophys Acta. 2004 Dec 24;1739(1):5-25. (Pubitemid 39647706)
68. Strauss KA, Morton DH, Puffenberger EG, Hendrickson C, Robinson DL, Wagner C, et al. Prevention of brain disease from severe 5,10- methylenetetrahydrofolate reductase deficiency. Mol Genet Metab. 2007 Jun;91(2):165-175. (Pubitemid 46765173)
69. Tward A, Xia YR,Wang XP, Shi YS, Park C, Castellani LW, et al. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation. 2002 Jul 23;106(4): 484-490. (Pubitemid 34803695)
70. Undas A, Brozek J, Jankowski M, Siudak Z, Szczeklik A, Jakubowski H. Plasma homocysteine affects fibrin clot permeability and resistance to lysis in human subjects. Arterioscler Thromb Vasc Biol. 2006 Jun;26(6):1397-1404. (Pubitemid 44305388)
71. Undas A, Jankowski M, Twardowska M, Padjas A, Jakubowski H, Szczeklik A. Antibodies to Nhomocysteinylated albumin as a marker for early-onset coronary artery disease in men. Thromb Haemost. 2005 Feb;93(2):346-350. (Pubitemid 40253742)
72. Undas A, Perla J, Lacinski M, Trzeciak W, Kazmierski R, Jakubowski H. Autoantibodies against N-homocysteinylated proteins in humans: implications for atherosclerosis. Stroke. 2004 Jun;35(6):1299-1304. (Pubitemid 38697447)
73. Undas A, Stepien E, Glowacki R, Tisonczyk J, Tracz W, Jakubowski H. Folic acid administration and antibodies against homocysteinylated proteins in subjects with hyperhomocysteinemia. Thromb Haemost. 2006 Sep;96(3):342-347. (Pubitemid 44377819)
74. Vos E. Homocysteine levels, paraoxonase 1 (PON1) activity, and cardiovascular risk. JAMA. 2008 Jul 9;300(2):168-169; author reply 9. (Pubitemid 351969310)
75. Yang X, Gao Y, Zhou J, Zhen Y, Yang Y, Wang J, et al. Plasma homocysteine thiolactone adducts associated with risk of coronary heart disease. Clin Chim Acta. 2006 Feb;364(1-2):230-234. (Pubitemid 43120647)
76. Yap S, Boers GH,Wilcken B,Wilcken DE, Brenton DP, Lee PJ, et al. Vascular outcome in patients with homocystinuria due to cystathionine beta-synthase deficiency treated chronically: a multicenter observational study. Arterioscler Thromb Vasc Biol. 2001 Dec;21(12):2080-2085. (Pubitemid 34219765)
77. Zimny J, Sikora M, Guranowski A, Jakubowski H. Protective mechanisms against homocysteine toxicity: the role of bleomycin hydrolase. J Biol Chem. 2006 Aug 11;281(32):22485-22492.